Homepage | Forward to a Friend | Make a Donation |
|
eLetter #661 | May 27, 2016 |
|
Early Bird Registration Rates Still Available for 2016 National Patient Education Conference
The 18th annual
National Patient Education Conference offers educational and networking
opportunities for people living with scleroderma, their caregivers, family
members and friends. We also offer a kids program at the conference that
is open to younger patients, their siblings or even the child of an adult
patient. Register now and take advantage of the Early Bird
Registration rates. Early Bird Rates are only available through this Tuesday, May 31. In addition to registering for the conference, we highly suggest you secure your hotel room. We are currently in a potential sell-out status. Join us in New Orleans, Louisiana from Friday, July 29, to Sunday,
July 31, 2016
Click here to register >>
|
A Positive Approach to Scleroderma
As we know, there is no cure for scleroderma and no conventional medical treatment that can reliably manage the disease. Andrew Weil, M.D. and Steven Gurgevich, Ph.D., provide some advice on how patients can education themselves about the disease. They also offer some excellent advice on treatment and how to find available resources.
|
Video: How Can My Family and I Manage Systemic Sclerosis Together?
The Federation of
European Scleroderma Associations (FESCA), has released a
series of videos that were recorded at the 4th Systemic Sclerosis World
Congress earlier this year. The workshops cover a variety of different
topics and features. This session addresses coping with scleroderma.
Click here to watch >>
|
6 Things People with Chronic Illness Share with Each Other
For people with a rare disease or other chronic illness, it doesn’t take much to relate to one another, regardless of the diagnosis. Commonalities can create an instant bond and understanding of someone else's life even if you are not experiencing the same symptoms.
Click here to read more >>
|
Clinical Trial Update
|
Cytori Fully Enrolls Pivotal United States Phase III Scleroderma Trial
Cytori Therapeutics, Inc. announced that its U.S. FDA-approved phase III STAR trial has enrolled its 80th patient (100% of target enrollment). All 80 patients enrolled thus far in both trial arms have been successfully treated without complications. Full trial data are expected to be available in mid-2017.
Click here for more >>
|
|
|
|
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
|
|
|